Semiconductor Inspection System Market Expected to Reach USD 8 Billion by 2022

Semiconductor Inspection System Market by Types (Wafer Inspection System, Mask Inspection System), by End Users (SMEs, Large Organization) – Forecast 2016-2022

Key players in the market are- KLA-Tencor (U.S.) ASML Holding (Netherlands), Applied Materials (U.S.), Lasertech (Japan), Hitachi High-Technologies (Japan), Nanometrics Incorporated (U.S.)

— Market Research Future

PUNE, MAHARASHTRA, INDIA, November 21, 2016 /EINPresswire.com/ — Market Research Future published a Half Cooked Research Report on Semiconductor Inspection System Market. The Global Market for Semiconductor Inspection System is majorly driven by factors such as high demand for electronic products and growth of IOT market.

Market Highlights

Global Semiconductor Inspection System Market is growing at a CAGR of ~12%. As the technology is growing, market for semiconductor is growing simultaneously and the market of Semiconductor Inspection System is completely dependent on the growth of semiconductor industry. Global Semiconductor Inspection System market has been valued at US ~3 billion in the year 2015 which is expected to grow at US $~8 billion by the end of forecast period owing to the factors, growing parent industry of semiconductor products and heavy demand for the electronic products.

Request a Sample Report @ https://www.marketresearchfuture.com/sample-request/global-semiconductor-inspection-system-market-research-report-forecast-2022

Key Players in Global Semiconductor Inspection System Market

The prominent players in the market of Semiconductor Inspection System are:

• KLA-Tencor (U.S.)
• ASML Holding (Netherlands)
• Applied Materials (U.S.)
• Lasertech (Japan)
• Hitachi High-Technologies (Japan)
• Nanometrics Incorporated (U.S.)
• Rudolph Technologies (U.S.)
• Nikon (Japan), JEOL (Japan)
• FEI Company (U.S.)

Taste the market data and market information presented through more than 30 market data tables and figures spread over 110 numbers of pages of the project report. Avail the in-depth table of content TOC & market synopsis on “Global Semiconductor Inspection System Research Report -Forecast to 2022

Access Report Details @ https://www.marketresearchfuture.com/reports/global-semiconductor-inspection-system-market-research-report-forecast-2022

Market Drivers:

Commenting on the report, an analyst from Market Research Future (MRFR)’s team said: Growing market of electronics and high demand for the electronic products are some of the major factor which is driving the market of Semiconductor Inspection System. Technological advancement such as introduction of Nano sensors and high power ICs and need of more safe products on the quality parameters are forcing the manufacturers to adopt the inspection system in their manufacturing process. Also high demand from automotive and consumer electronic product manufacturers for the ICs and other semiconductor products are supporting the market.

Market Research Future Analysis:

Market Research Future analysis shows that the market of Semiconductor Inspection System will rise in the coming period. As the new technologies are being introduced and concept of smart cities, autonomous vehicles are coming into picture which will involve lots of electronic products will lead to the Semiconductor Inspection System market to new heights.

The Early Diners are Offered Free Customization – Up to 20% on this Report.

Make an Enquiry for this Report @ https://www.marketresearchfuture.com/enquiry/global-semiconductor-inspection-system-market-research-report-forecast-2022

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Akash Anand
Market Research Future
+1 646 845 9312
email us here


Source: EIN Presswire

IT Governance offers free trials of their ISO 27001, PCI DSS and EU GDPR documentation toolkits, and many more

ELY, CAMBRIDGESHIRE, UNITED KINGDOM, November 18, 2016 /EINPresswire.com/ — IT Governance, the leading provider of compliance documentation toolkits, offers free documentation toolkit trials to help organisations accelerate their compliance projects and gain certification to standards such as ISO 27001, the PCI DSS, ISO 9001 and ISO 20000.

Alan Calder, the founder and chief executive officer of IT Governance, said: “Compliance projects require organisations to develop and update policies and procedures in conformity with the standards, which can result in the laborious process of creating a large number of documents.

“Every policy and procedure needs to be researched, developed, approved and deployed. By using documentation toolkits, organisations can substantially reduce the time and costs associated with compliance and certification.”

“Our toolkits are proven to help organisations streamline their management system implementation projects by ensuring that all control areas are covered and professionally addressed, ultimately minimising the possibility of error,” Alan Calder continued.

Organisations looking to accelerate their ISO 27001 information security management system (ISMS) compliance project can take advantage of IT Governance’s ISO 27001:2013 ISMS Documentation Toolkit. The easy-to-use document templates reduce the room for error and enable easy integration with the organisation’s current procedures and processes.

Moreover, the ITSM, ITIL & ISO/IEC 20000 Implementation Toolkit is designed to help organisations meet the documentation requirements of ISO 20000 using ITIL best-practice processes. Developed by service management experts Shirley Lacy and Jenny Dugmore, the toolkit offers an optimal route to implementing service management best practice and achieving ISO 20000 certification.

By May 2018, organisations processing data on European residents will need to meet the requirements of the General Data Protection Regulation (GDPR). To help organisations create and update appropriate policies and procedures, and to facilitate compliance with the GDPR, IT Governance offers the EU GDPR Documentation toolkit.

Organisations wishing to implement a management system or achieve compliance with the GDPR can take advantage of IT Governance’s free documentation toolkit trails.

To download a free trail of one of IT Governance’s documentation toolkits, please visit IT Governance’s website, email servicecentre@itgovernance.co.uk or call +44 (0) 845 070 1750.

– Ends –

NOTES TO EDITORS

IT Governance Ltd is the single-source provider of books, tools, training and consultancy for IT governance, risk management and compliance. It is a leading authority on data security and IT governance for business and the public sector. IT Governance is ‘non-geek’, approaching IT issues from a non-technology background and talking to management in its own language. Its customer base spans Europe, the Americas, the Middle East and Asia. More information is available at www.itgovernance.co.uk.

Mihaela Jucan
IT Governance Ltd
00448450701750
email us here


Source: EIN Presswire

Bring Your Own Device (BYOD) Market Analysis by (Device, Industry), Global Research Report and Forecasting to 2016-2022



Market Research Future

Market research future published a half cooked research report on Global Bring Your Own Device Market that contains the information from 2016 to 2022.

PUNE, MAHARASHTRA, INDIA, November 21, 2016 /EINPresswire.com/ — Industry News
• In August 2016, AirWatch announced the launch of AirWatch Express which will speed up and simplify the mobile device management.

• In July 2016, AirWatch introduces a new identity defined workstation, an upgrade to existing workstation ONE.

Key players
o IBM Corporation (U.S.)
o Hewlett-Packard (U.S.)
o Alcatel-Lucent (France)
o Apperian (U.S.)
o AirWatch (U.S.)
o AT&T (U.S.)
o Cisco Systems Inc. (U.S.)
o Duo Security (U.S.)
o Good Technology, Inc. (U.S.)
o Oracle Corporation (U.S.)

Get a Sample Report @ https://www.marketresearchfuture.com/sample-request/bring-your-own-device-market-research-report-global-forecast-2022

Market Scenario
BYOD or Bring your own device refers to allowing the employees to bring their personal devices such as mobile phones, laptops, tablets to their work place and use them to access the privileged company information. Global BYOD Market has been valued at US $XX billion in the year 2015 which is expected to grow at US $XX billion by the end of forecasted period with the CAGR of XX%. Increase in the ration of clients bringing their own devices to workplace is driving the market.

Market Segmentation
By Device:
o Smartphone
o Tablets
o Laptops

By Industry:
o IT
o Manufacturing
o Telecommunication
o Entertainment
o Healthcare

Taste the market data and market information presented through more than 70 market data tables and figures spread in 110 numbers of pages of the project report. Avail the in-depth table of content TOC & market synopsis on “Bring Your Own Device Market Research Report- Global Forecast 2022

Study Objective of Bring Your Own Device (BYOD) Market
o To provide detailed analysis of the market structure along with forecast of the various segments and sub-segments of the Global Bring Your Own Device Market

o To provide insights about factors affecting the market growth

o To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- North America, Europe, Asia, and Rest of the World (ROW)

o To analyze the Bring Your Own Device market based on various factors- value chain analysis, porter’s five force analysis etc.

o To provide country level analysis of the market with respect to the current market size and future prospective

o To provide country level analysis of the market for segment by device by industry and sub-segments

o To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market

o To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Global Bring Your Own Device Market

Browse Report @ https://www.marketresearchfuture.com/reports/bring-your-own-device-market-research-report-global-forecast-2022

Regional Analysis
North America is dominating the market of BYOD with the market share of XX%. High employment ration and high consumption of consumer electronic products such as smartphones and tablets are driving the market. Europe stands as second biggest market for BYOD in terms of revenue generation which holds XX% of market share. Asia-Pacific has emerged as fastest growing market with the with the CAGR of XX% which has been valued at US $XX billion in the year 2015 and expected to reach at US $XX billion by the end of forecasted period.

Table of Content
1. Report Prologue
2. Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
2.3 Market Structure
2.4. Market Segmentation
3. Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
3.5 Forecast Model
4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Mega Trends
4.5 Macroeconomic Indicators
5. Market Factor Analysis
5.1 Value Chain Analysis
5.2 Porters Five Forces
5.3 Demand & Supply: Gap Analysis
5.4 Pricing Analysis
5.5 Investment Opportunity Analysis
5.6 Merger and Acquisition Landscape
5.7 Up-Coming Trends In BYOD Market
5.7.1 Market Trends
5.7.2 Technological Trends
Continue……….

Get Full Table of Content (TOC) with List of Table & Figures @ https://www.marketresearchfuture.com/request-toc/bring-your-own-device-market-research-report-global-forecast-2022

This research report provides the insights, on various levels of analyses such industry analysis, market share analysis leading market players and their profiles. This report also helps in studying the target segments by providing views on emerging & high-growth segments and market conclusion. Together the market data comprise and discuss with the basic assessments on the competitive scenarios & strategies, of the global Bring Your Own Device market, including the high-growth regions, countries and their political, economic and technological environments. Furthermore, the project report also provides the views over the historical market values of the same.

Related Report
Cluster Computing Market, by Service Type (HPC IAAS, HPC PAAS, Data Organization, Cluster Software), by Deployment (On Premises, On Cloud), By Organization Size (Large Business Unit and Small Business Unit), By Vertical (Life Science, Industrial, Banking, Retail) – Forecast 2016-2022 https://www.marketresearchfuture.com/reports/global-cluster-computing-market-research-report-forecast-2022

About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Akash Anand
Market Research Future
+1 646 845 9312
email us here


Source: EIN Presswire

Industry Showcase to Feature Technical Expertise on the Next Generation of Armoured Vehicle C4ISTAR Next Spring

Future Armoured Vehicles Situational Awareness 2017

Future Armoured Vehicles Attendees

Future Armoured Vehicles Situational Awareness 2017 to include updates from those developing the equipment and vetronic architectures for combat vehicle C4ISTAR

Unrivalled insight into the technology available for military applications…

— Former Head of Force Protection, UK MoD

LONDON, ENGLAND, UNITED KINGDOM, November 21, 2016 /EINPresswire.com/ — SMi Group’s next annual conference on Future Armoured Vehicles Situational Awareness will feature an industry spotlight when it returns to Central London on 29th & 30th March 2017.

With an increased demand for modern mechanised forces to act quickly and decisively, the armoured vehicle has witnessed a step change in its role as a gatherer and distributor of intelligence within the network. Fully digitalised platforms now set the standard and within the British Army alone, the next generation infantry fighting vehicle, Ajax, is set to be the ‘eyes and ears’ of the battlefield.

The Future Armoured Vehicles Situational Awareness conference is purely dedicated to exploring the role of combat vehicles as a key deliverer of land ISTAR.

As well as being supported by the UK MoD and featuring a panel of senior representatives from international defence organisations, the industry spotlight at Future Armoured Vehicles Situational Awareness will provide technical expertise from those developing the sensors, optronics, communication equipment and vetronic architectures enabling the next generation of combat vehicle C4ISTAR.

Highlights will include the following industry presentations:

Situational Awareness Capability within the Puma Infantry Fighting Vehicle by Mr Tobias Baumart, Project Manage, LAND 400 PUMA, PSM; and Mr Martin Röder, Project Manager, Information Technology, PSM.

Attendees will hear an update on the The Projekt System & Management GmbH (PSM) joint venture of Krauss-Maffei Wegmann GmbH & Co. KG and Rheinmetall Landsysteme GmbH. With a focus on the Bundeswehr, the talk will explore improvement over the legacy Marder IFV and provide insight into visual situation awareness for crew and passengers via optronics and display systems. MUSS active protection systems for detection and defeat of threats will also be discussed.

Many Situations, Many Sensors, Many Effectors by Mr Guy Davies, Capability Manager, Vehicle Systems, Land and Naval Defence Electronics Division, Leonardo MW Ltd.

The case study by Leonardo MW Ltd will look at the multifaceted face of land mission systems exploring a situational awareness, survivability and integrated mission system perspective.

Vehicle Situational Awareness and Threat Detection from a Full 360° Azimuth: Findings from the Development of Antares Mr Thierry Midavaine, Technical Director, Thales Optronique SA

What operational requirements have driven development of Antares? Thales Optronique SA will provide insight in ongoing work with the French Army’s Scorpion Programme with key findings from research on threat detection and situational awareness capability.

Further information including a detailed agenda and full speaker line-up is available at www.armouredvehicles-sa.com

Future Armoured Vehicles Situational Awareness
29th & 30th March 2017,
Copthorne Tara Hotel, Kensington, London, UK

—end —

Contact information:

For media enquiries contact Teri Arri on Tel: +44 20 7827 6162 / Email: tarri@smi-online.co.uk
To register onto the event visit www.armouredvehicles-sa.com or contact James Hitchen on Tel +44 (0) 207 827 6054 / Email jhitchen@smi-online.co.uk
For sponsorship packages contact Justin Predescu Tel: +44 (0) 207 827 6130 / Email: jpredescu@smi-online.co.uk

About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Teri Arri
SMi Group
+442078276162
email us here


Source: EIN Presswire

Vancomycin -Resistant Enterococcus faecium Infections Therapeutic and Drug Pipeline Review H2



Wise.Guy.

Vancomycin -Resistant Enterococcus faecium Infections Treatment Pipeline Review H2 2016

PUNE, INDIA, November 21, 2016 /EINPresswire.com/ — Get Sample Report @ https://www.wiseguyreports.com/sample-request/752827-vancomycin-resistant-enterococcus-faecium-infections-pipeline-review-h2-2016

Pathogenic strains of Enterococcus resistant to vancomycin are termed as Vancomycin-Resistant Enterococcus (VRE). Vancomycin-resistant enterococci have become a source of nosocomial infections. The symptoms of Vancomycin-resistant enterococci infection depend on where the infection lies. The bacteria usually infect the intestines, wounds and urinary tract. In case of wound infection, the area infected will be red and tender as well as swollen. In case of urinary tract infection, back pain and burning could occur when urination takes place. Other symptoms include nausea, fever, chills, severe headaches and diarrhea. Prevention requires effective hygienic practices.

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Vancomycin-Resistant Enterococcus faecium Infections – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Vancomycin-Resistant Enterococcus faecium Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 18 and 6 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively.Vancomycin-Resistant Enterococcus faecium Infections.

Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease).
– The pipeline guide reviews pipeline therapeutics for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease)

Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Vancomycin-Resistant Enterococcus faecium Infections Overview 9
Therapeutics Development 10
Pipeline Products for Vancomycin-Resistant Enterococcus faecium Infections – Overview 10
Pipeline Products for Vancomycin-Resistant Enterococcus faecium Infections – Comparative Analysis 11
Vancomycin-Resistant Enterococcus faecium Infections – Therapeutics under Development by Companies 12
Vancomycin-Resistant Enterococcus faecium Infections – Therapeutics under Investigation by Universities/Institutes 14
Vancomycin-Resistant Enterococcus faecium Infections – Pipeline Products Glance 15
Clinical Stage Products 15
Early Stage Products 16
Vancomycin-Resistant Enterococcus faecium Infections – Products under Development by Companies 17
Vancomycin-Resistant Enterococcus faecium Infections – Products under Investigation by Universities/Institutes 19
…Continued

Access Report @ https://www.wiseguyreports.com/reports/752827-vancomycin-resistant-enterococcus-faecium-infections-pipeline-review-h2-2016

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Bipolar Disorder Therapeutic and Drug Pipeline Review H2



Wise.Guy.

Bipolar Disorder Treatment Pipeline Review H2 2016

PUNE, INDIA, November 21, 2016 /EINPresswire.com/ — Get Sample Report @ https://www.wiseguyreports.com/sample-request/752826-bipolar-disorder-manic-depression-pipeline-review-h2-2016

Bipolar disorder was formerly called manic depression. It is a form of major affective disorder, or mood disorder, defined by manic or hypomanic episodes. Symptoms include decreased appetite and/or weight loss, or overeating and weight gain, fatigue, decreased energy, being slowed down, insomnia, early-morning awakening, or oversleeping, restlessness and irritability. The predisposing factors include age, stress and family history. Treatment includes anticonvulsants, antipsychotics and antidepressants.

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Bipolar Disorder (Manic Depression) – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Bipolar Disorder (Manic Depression) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bipolar Disorder (Manic Depression) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Bipolar Disorder (Manic Depression) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 3, 10, 6 and 4 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 1 and 2 molecules, respectively.Bipolar Disorder (Manic Depression).

Bipolar Disorder (Manic Depression) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Bipolar Disorder (Manic Depression) (Central Nervous System).
– The pipeline guide reviews pipeline therapeutics for Bipolar Disorder (Manic Depression) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Bipolar Disorder (Manic Depression) (Central Nervous System) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Bipolar Disorder (Manic Depression) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Bipolar Disorder (Manic Depression) (Central Nervous System)

Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Bipolar Disorder (Manic Depression) (Central Nervous System).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Bipolar Disorder (Manic Depression) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Bipolar Disorder (Manic Depression) Overview 10
Therapeutics Development 11
Pipeline Products for Bipolar Disorder (Manic Depression) – Overview 11
Pipeline Products for Bipolar Disorder (Manic Depression) – Comparative Analysis 12
Bipolar Disorder (Manic Depression) – Therapeutics under Development by Companies 13
Bipolar Disorder (Manic Depression) – Therapeutics under Investigation by Universities/Institutes 15
Bipolar Disorder (Manic Depression) – Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Bipolar Disorder (Manic Depression) – Products under Development by Companies 19
Bipolar Disorder (Manic Depression) – Products under Investigation by Universities/Institutes 21
Bipolar Disorder (Manic Depression) – Companies Involved in Therapeutics Development 22
Aequus Pharmaceuticals Inc. 22
Amorsa Therapeutics Inc. 23
AstraZeneca Plc 24
Biogen Inc 25
Delpor, Inc. 26
Intas Pharmaceuticals Ltd. 27
…Continued

Access Report @ https://www.wiseguyreports.com/reports/752826-bipolar-disorder-manic-depression-pipeline-review-h2-2016

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Muscular dystrophy Therapeutic and Drug Pipeline Review H2



Wise.Guy.

Muscular dystrophy Treatment Pipeline Review H2 2016

PUNE, INDIA, November 21, 2016 /EINPresswire.com/ — Get Sample Report @ https://www.wiseguyreports.com/sample-request/752823-muscular-dystrophy-pipeline-review-h2-2016

Muscular dystrophy is a group of diseases in which muscle fibers are unusually susceptible to damage. These damaged muscles become progressively weaker. Symptoms usually appear before age 6 and may appear as early as infancy. They may include fatigue, learning difficulties, intellectual disability, muscle weakness and progressive difficulty walking.

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Muscular Dystrophy – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Muscular Dystrophy (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Muscular Dystrophy (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 2, 24 and 14 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 3 and 4 molecules, respectively.Muscular Dystrophy.

Muscular Dystrophy (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Muscular Dystrophy (Musculoskeletal Disorders).
– The pipeline guide reviews pipeline therapeutics for Muscular Dystrophy (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Muscular Dystrophy (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Muscular Dystrophy (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Muscular Dystrophy (Musculoskeletal Disorders)

Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Muscular Dystrophy (Musculoskeletal Disorders).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Muscular Dystrophy (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Muscular Dystrophy Overview 8
Therapeutics Development 9
Pipeline Products for Muscular Dystrophy – Overview 9
Pipeline Products for Muscular Dystrophy – Comparative Analysis 10
Muscular Dystrophy – Therapeutics under Development by Companies 11
…Continued

Access Report @ https://www.wiseguyreports.com/reports/752823-muscular-dystrophy-pipeline-review-h2-2016

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Diphtheria Therapeutic and Drug Pipeline Review H2



Wise.Guy.

Diphtheria Treatment Pipeline Review H2 2016

PUNE, INDIA, November 21, 2016 /EINPresswire.com/ — Get Sample Report @ https://www.wiseguyreports.com/sample-request/752819-diphtheria-pipeline-review-h2-2016

Diphtheria is a bacterial infection that affects the membranes of the throat and nose. If left untreated, diphtheria can cause severe damage to kidneys, nervous system, and heart. Symptoms include sore throat and hoarseness, swollen glands (enlarged lymph nodes) in neck, nasal discharge, fever and chills and malaise. Treatment includes antitoxins and antibiotics.

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Diphtheria – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Diphtheria (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diphtheria (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Diphtheria and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 10, 1, 5, 1, 7 and 3 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 1 and 2 molecules, respectively.Diphtheria.

Diphtheria (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Diphtheria (Infectious Disease).
– The pipeline guide reviews pipeline therapeutics for Diphtheria (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Diphtheria (Infectious Disease) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Diphtheria (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Diphtheria (Infectious Disease)

Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Diphtheria (Infectious Disease).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Diphtheria (Infectious Disease) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Diphtheria Overview 9
Therapeutics Development 10
Pipeline Products for Diphtheria – Overview 10
Pipeline Products for Diphtheria – Comparative Analysis 11
Diphtheria – Therapeutics under Development by Companies 12
Diphtheria – Therapeutics under Investigation by Universities/Institutes 14
Diphtheria – Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Diphtheria – Products under Development by Companies 18
Diphtheria – Products under Investigation by Universities/Institutes 20
Diphtheria – Companies Involved in Therapeutics Development 21
Beijing Minhai Biotechnology Co., Ltd 21
BioClonetics Immunotherapeutics, Inc. 22
…Continued

Access Report @ https://www.wiseguyreports.com/reports/752819-diphtheria-pipeline-review-h2-2016

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Irritable Bowel Syndrome Therapeutic and Drug Pipeline Review H2



Wise.Guy.

Irritable Bowel Syndrome Treatment Pipeline Review H2 2016

PUNE, INDIA, November 21, 2016 /EINPresswire.com/ — Get Sample Report @ https://www.wiseguyreports.com/sample-request/752817-irritable-bowel-syndrome-pipeline-review-h2-2016
Inflammatory Bowel Diseases (IBD) is a broad term that describes conditions with chronic or recurring immune response and inflammation of the gastrointestinal tract. Signs and symptoms include abdominal cramps and pain, diarrhea that may be bloody, weight loss, loss of appetite and fever. The predisposing factors include age, family history, smoking and some pain killers. Treatment includes corticosteroids, immune suppressors, antibiotics and pain relievers.

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Irritable Bowel Syndrome – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Irritable Bowel Syndrome (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Irritable Bowel Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 10, 6, 9 and 1 respectively.Irritable Bowel Syndrome.

Irritable Bowel Syndrome (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Irritable Bowel Syndrome (Gastrointestinal).
– The pipeline guide reviews pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Irritable Bowel Syndrome (Gastrointestinal) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Irritable Bowel Syndrome (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal)

Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Irritable Bowel Syndrome (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Irritable Bowel Syndrome Overview 10
Therapeutics Development 11
Pipeline Products for Irritable Bowel Syndrome – Overview 11
Irritable Bowel Syndrome – Therapeutics under Development by Companies 12
Irritable Bowel Syndrome – Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Irritable Bowel Syndrome – Products under Development by Companies 17
Irritable Bowel Syndrome – Companies Involved in Therapeutics Development 19
4D Pharma Plc 19
A. Menarini Industrie Farmaceutiche Riunite Srl 20
…Continued

Access Report @ https://www.wiseguyreports.com/reports/752817-irritable-bowel-syndrome-pipeline-review-h2-2016

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Indian Non-IP CCTV Camera Market to Reach INR 38.65 crore with 27.16% CAGR Forecast to 2021

Non-IP CCTV Camera Market 2016 Indian Trends, Market Share, Industry Size, Growth, Opportunities, and Forecast to 2021

PUNE, INDIA, November 21, 2016 /EINPresswire.com/ — Closed Circuit Television (CCTV) is a system which uses cameras to transmit signal to a specific place which helps to monitor any kind of activities going on in any area. CCTV is a growing market as it is being widely used in many applications all over the world. Technology is the main concern in the CCTV camera market in India. IP (Internet Protocol) and non-IP CCTV cameras are the two types of CCTV cameras that are traditionally used. Now based on the different type of camera used, bifurcation is made like dome cameras, bullet and box shaped cameras, PTZ cameras etc. CCTV cameras was primarily used in the commercial segment for the surveillance, but with increasing thefts, burglary and other criminal activities all over the world, residential sector is also showing keen interest in the CCTV camera market for security purpose. This report is about the market size of the CCTV camera market in India how with the increasing number of terrorist activities, the demand of CCTV market is continuously increasing. This report describes the different technologies that are used in the CCTV market and the upcoming technologies that would drive the market. The report also reveals the trend in this industry is shifting to people becoming more conscious about the security and the increasing thefts than being pessimist about the cost involved in buying the product.
Request a sample report @ https://www.wiseguyreports.com/sample-request/744785-india-non-ip-cctv-camera-market-outlook-2021
The India CCTV camera market is anticipated to generate substantial revenue of about INR 38.65 crore till 2021. Asia Pacific and America holds the largest share of the India market and act as one of the main driver for the market. India and China are the countries with the highest potential for the CCTV camera market. Technology-wise, wireless CCTV cameras are becoming a trend apart from the traditional non-IP and IP which is widely used currently. Non –IP technology consisting of analog and HD CCTV cameras dominate the market currently. Dome shaped cameras dominate the CCTV market in terms of type of camera used. PTZ (pan, tilt, zoom) is a recent technology which allows a 360 degree view of the surveillance are and also gives added features to zoom by covering a larger section of area.
According to “India CCTV Camera Non-IP Market Outlook, 2021”, the India CCTV Camera market is expected to grow with a CAGR of about 27.16% in the period from 2016 to 2021. Technology wise non-IP dominates the Indian market but in the coming years. Analog is technology which is in a depleting stage and its share is expected to be taken by the IP technology and the HD type CCTV camera. Dome typed cameras are the most widely used cameras in any sectors. Commercial segment is the driver of the CCTV market in India with the increasing count of SOHO’s and SME’s. With the increasing security concerns, residential sector would also be one of the factors for the increasing market. As criminal activities are more in the northern region of India, North dominates the market in terms of revenue. According to the technology different players are present in the market. In the non-IP segment the market is consisting of players like CP Plus, Dahua and Prama Hikvision constituting to more than 70% of the market. The widespread use of CCTV camera in various industries like government sectors, SOHO’s and SME’s, Banking, Hospitality and other commercial establishment will make the CCTV cameras market to increase with a robust growth.
Complete report details @ https://www.wiseguyreports.com/reports/744785-india-non-ip-cctv-camera-market-outlook-2021
Key points in table of content
1. Executive Summary
2. India CCTV Camera Market Outlook
2.1. Market Size By Value
2.2. Market Share
2.2.1. By Country
2.2.2. By Geography
2.2.3. By Technology
2.2.4. By Company
3. India Electronic Security Market Outlook
3.1. Market Size By Value
3.2. Market Share By Segment
4. India CCTV Camera Market Outlook
4.1. Market Size By Value with technology division
4.2. Market Size By Volume with technology division
4.3. Market Share
4.3.1. By End User Segment
4.3.2. By Region
4.3.3. By Industry
4.3.4. By City
5. India Non – IP CCTV Market Outlook
5.1. Market Size
5.1.1. By Value
5.1.2. By Volume
5.2. Market Share
5.2.1. By Company
5.2.2. By Segment
5.2.3. Analog CCTV Market Outlook
5.2.3.1. Market Size By Value
5.2.3.2. Market Size By Volume
5.2.3.3. By Camera Type
5.2.4. HD CCTV Market Outlook
5.2.4.1. Market Size By Value
5.2.4.2. Market Size By Volume
5.2.4.3. By Camera Type
5.3. Organized vs. Unorganized Market Outlook
5.4. Pricing Analysis
6. India Economic Profile
7. Channel Partner Analysis
8. Market Trends & Developments
8.1. Thermal Cameras
8.2. Video Analytics
8.3. Cloud Video Surveillance
8.4. 360 degree camera
9. Competitive Landscape
9.1. Porters Five Forces
9.2. Company Profiles
9.2.1. CP PLUS gmbh & Co. KG.
9.2.2. Dahua Technology Co. Ltd.
9.2.3. Honeywell International Inc.
9.2.4. Panasonic Corporation
9.2.5. Prama Hikvision India Pvt. Ltd.
9.2.6. Micro Technology India Pvt. Ltd.
9.2.7. Zicom Security System
10. Disclaimer
Get this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=744785
Contact US:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire